Drug Profile
NC 102
Alternative Names: NC102Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Naia Limited
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 19 May 2017 Preclinical trials in Type-2 diabetes mellitus in USA before May 2017 (Naia Limited pipeline, May 2017)
- 19 May 2017 Naia Limited plans a clinical trial for Type-2 diabetes (Naia Limited pipeline, May 2017)